Self-derivation of new factual knowledge is crucial for building a knowledge base. In three experiments, we investigated self-derivation about prescription medications. In Experiment 1, adults self-derived new knowledge across textual materials on 40% of trials. Participants in Experiment 2 performed similarly (42%), even when half the information was presented in videos. It was crucial that participants received both learning episodes to successfully self-derive: control condition participants received half the necessary information and performed significantly lower. When a delay was imposed between related facts in Experiment 3, participants self-derived on only 33% of trials and performance did not differ from the control condition. The present research expanded our understanding of adults' learning and self-derivation across media about medications. It revealed room for improvement in adults' learning and self-derivation about health information. This work suggests the need to identify factors that alter performance, including better understanding of the properties of information sources.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176838 | PMC |
http://dx.doi.org/10.1002/acp.3926 | DOI Listing |
Alzheimers Dement
December 2024
Icahn School Of Medicine at Mount Sinai, New York, NY, USA.
Background: Despite increasing knowledge of the etiology of neurodegenerative diseases, translation of these benefits into therapeutic advances for Alzheimer's Disease and related diseases (ADRD) has been slow. Drug repurposing is a promising strategy for identifying new uses for approved drugs beyond their initial indications. We developed a high-throughput drug screening platform aimed at identifying drugs capable of reducing proteotoxicity in vivo (Aß toxicity in Caenorhabditis elegans) AND inhibiting microglial inflammation (TNF-alpha IL-6), both implicated in driving AD(figure attached with sample of results in C.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan.
In Japan, the regulatory authority approved the drug in September 2023, and on December 20, it became available for prescription country-wide under the health insurance system. However, there are strict patient, physician, and facility requirements for the prescription of Lecanemab, and various problems are anticipated in its future implementation and widespread use in society. Lecanemab is the first anti-Aβ antibody in Japan, and even dementia specialists do not have sufficient knowledge and experience in its introduction, evaluation of efficacy, and evaluation and handling of side effects.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Unitiy Hospital, Rochester, NY, USA.
Background: Psychotropic drug prescriptions are commonly used to manage behavioral and psychological symptoms of dementia in elderly patients in long-term care facilities. The prevalence of psychotropic drug use in this population raises concerns due to potential side effects, polypharmacy and quality of life of the patients.
Aim: To assess the trends in psychotropic drug prescriptions for elderly patients with dementia following the continuous implementation of multimodal comprehensive care communication skills training for staff in a long-term care hospital.
Alzheimers Dement
December 2024
University of Calgary, Calgary, AB, Canada.
Background: The overuse of antipsychotics in persons with dementia in long-term care (LTC) has been a source of clinical concern, public attention, and policy intervention for over 30 years. Targeted quality improvement, broader awareness of risks, and other initiatives have resulted in substantial reductions in antipsychotic use in LTC settings in North America and elsewhere. Limited evidence suggests that reductions in antipsychotic use may be resulting in unintended consequences, such as substitution with alternate, but similarly harmful, psychotropic medications.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Prevent Alzheimer's Disease 2020, Inc., Rockville, MD, USA.
Background: Disparities in the quality and timeliness of care for Alzheimer's disease (AD) are well documented. This study assessed the impact of demographic characteristics on the diagnosis and management of early AD patients in community-based settings.
Method: This cross-sectional study abstracted medical chart data for patients aged 50-89 years who had newly diagnosed early AD (mild cognitive impairment [MCI] or mild AD) within the past 2 years and a clinic visit within the past 12 months.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!